ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Eli Lilly & Co. and Hutchison MediPharma have agreed to collaborate on the research and development of new drugs. Under the deal, Shanghai-based Hutchison will come up with new clinical candidates in exchange for an up-front payment, R&D support fees, and milestone payments amounting to as much as $29 million per candidate. In addition, Hutchison will earn royalties in the event that drugs are commercially launched. Clinical development will be Lilly's responsibility. Lilly has conducted drug research in Shanghai for a number of years. It is the exclusive customer of Shanghai ChemExplorer, a contract research firm with several hundred scientists. Employing 140 scientists in Shanghai's Zhangjiang Hi-Tech Park, Hutchison MediPharma is a subsidiary of Chi-Med, a London-listed holding company focusing on China's pharmaceutical and health care sector. Hutchison Whampoa, one of Hong Kong's largest business groups, owns a majority stake in Chi-Med. Earlier this month, WuXi Pharmatech, one of the largest Shanghai-based drug research firms, made an initial public offering of stock. WuXi counts nine of the world's top 10 drug companies as customers.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter